Literature DB >> 23427233

Resveratrol is a potent inhibitor of vascularization and cell proliferation in experimental endometriosis.

J Rudzitis-Auth1, M D Menger, M W Laschke.   

Abstract

STUDY QUESTION: Does the phytochemical compound resveratrol inhibit vascularization of endometriotic lesions? SUMMARY ANSWER: Resveratrol suppresses the development of new microvessels in endometriotic lesions by inhibiting endothelial cell proliferation. WHAT IS KNOWN ALREADY: Establishment and progression of endometriosis is crucially dependent on angiogenesis. Resveratrol is a pleiotropic agent, which dose-dependently suppresses the development of new blood vessels. STUDY DESIGN, SIZE, DURATION: This was a randomized study in a mouse model of endometriosis. Twenty female BALB/c mice with surgically induced endometriosis were treated with resveratrol (40 mg/kg/day, n = 10) or vehicle (n = 10) for 4 weeks. MATERIAL, SETTING,
METHODS: Peritoneal and mesenteric endometriotic lesions were surgically induced by uterine tissue transplantation into the abdominal cavity of BALB/c mice. The animals were daily treated with resveratrol (40 mg/kg) or vehicle by oral gavage. Lesion growth, vascularization, apoptosis and cell proliferation were subsequently analyzed by means of high-resolution ultrasound imaging, caliper measurements, histology and immunohistochemistry throughout an observation period of 4 weeks. MAIN RESULTS AND THE ROLE OF CHANCE: Resveratrol inhibited angiogenesis in peritoneal and mesenteric endometriotic lesions, as indicated by a significantly reduced microvessel density when compared with controls. Additional immunohistochemical analyses revealed that this was caused by a decreased proliferating activity of CD31-positive endothelial cells in the newly developing microvasculature of the lesions. In line with these findings, lesions in resveratrol-treated mice exhibited a reduced growth rate and a smaller final size than controls. This was associated with lower numbers of proliferating cell nuclear antigen- and Ki67-positive stromal and glandular cells. Apoptotic cells were not detectable in either group. To limit the role of chance, the experiments were conducted under standardized laboratory conditions with appropriate controls. Statistical significance was accepted for a value of P < 0.05. LIMITATIONS, REASONS FOR CAUTION: Endometriotic lesions were surgically induced by uterine tissue transplantation without the use of pathological endometriotic tissue of human origin. Therefore, the results obtained in this mouse model may not fully correlate to human patients with endometriosis. WIDER IMPLICATIONS OF THE
FINDINGS: Resveratrol is a potent inhibitor of vascularization in endometriotic lesions. This, most probably, causes the suppression of lesion growth. Accordingly, resveratrol represents a promising candidate therapy for future phytochemical treatment of endometriosis. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by a grant of the 'Freunde des Universitätsklinikums des Saarlandes'. The authors have no conflicts of interest to declare.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23427233     DOI: 10.1093/humrep/det031

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  20 in total

1.  Effect of induced peritoneal endometriosis on oocyte and embryo quality in a mouse model.

Authors:  J Cohen; A Ziyyat; I Naoura; N Chabbert-Buffet; S Aractingi; E Darai; B Lefevre
Journal:  J Assist Reprod Genet       Date:  2014-11-16       Impact factor: 3.412

2.  Vascular endothelial growth factor receptor-2 inhibitor cediranib causes regression of endometriotic lesions in a rat model.

Authors:  Fang Liu; Li Wang; Xian-Xia Zhang; Shu-Yun Min; Yi-Xuan Liu; Zhi Zuo; Zhi-Xing Jin; Zhi-Ling Zhu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  Combination therapy with telmisartan and parecoxib induces regression of endometriotic lesions.

Authors:  Anca Nenicu; Yuan Gu; Christina Körbel; Michael D Menger; Matthias W Laschke
Journal:  Br J Pharmacol       Date:  2017-07-06       Impact factor: 8.739

4.  RESVERATROL BINDS NUCLEAR RECEPTOR 4A1 (NR4A1) AND ACTS AS AN NR4A1 ANTAGONIST IN LUNG CANCER CELLS.

Authors:  Lei Zhang; Greg Martin; Kumaravel Mohankumar; Joshua Trae Hampton; Wenshe Rayi Liu; Stephen Safe
Journal:  Mol Pharmacol       Date:  2022-06-09       Impact factor: 4.054

5.  Effects of ranibizumab and zoledronic acid on endometriosis in a rat model.

Authors:  Eda Ureyen Ozdemir; Ertan Adali; Mine Islimye Taskin; Altug Yavasoglu; Huseyin Aktug; Fatih Oltulu; Umit Inceboz
Journal:  Arch Gynecol Obstet       Date:  2022-02-25       Impact factor: 2.493

6.  Analysis of the efficacy of resveratrol treatment in patients with scarred uterus.

Authors:  Huashu Ma; Zongxu Qiao
Journal:  Exp Ther Med       Date:  2018-05-03       Impact factor: 2.447

7.  Effects of ranibizumab and zoledronic acid on endometriosis in a rat model.

Authors:  Eda Ureyen Ozdemir; Ertan Adali; Mine Islimye Taskin; Altug Yavasoglu; Huseyin Aktug; Fatih Oltulu; Umit Inceboz
Journal:  Arch Gynecol Obstet       Date:  2021-06-03       Impact factor: 2.493

Review 8.  Can Endometriosis-Related Oxidative Stress Pave the Way for New Treatment Targets?

Authors:  Luciana Cacciottola; Jacques Donnez; Marie-Madeleine Dolmans
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

Review 9.  Phytoestrogens for the Management of Endometriosis: Findings and Issues.

Authors:  Xia Cai; Min Liu; Bing Zhang; Shao-Jie Zhao; Shi-Wen Jiang
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-14

10.  Luminal epithelium in endometrial fragments affects their vascularization, growth and morphological development into endometriosis-like lesions in mice.

Authors:  Dilu Feng; Michael D Menger; Hongbo Wang; Matthias W Laschke
Journal:  Dis Model Mech       Date:  2013-11-28       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.